Edition:
United Kingdom

Bergenbio ASA (BGBIO.OL)

BGBIO.OL on Oslo Stock Exchange

28.90NOK
14 Dec 2018
Change (% chg)

kr-0.90 (-3.02%)
Prev Close
kr29.80
Open
kr29.00
Day's High
kr29.50
Day's Low
kr28.00
Volume
39,715
Avg. Vol
82,188
52-wk High
kr54.80
52-wk Low
kr19.80

Summary

Name Age Since Current Position

Stein Annexstad

73 2017 Independent Chairman of the Board

Richard Godfrey

51 2008 Chief Executive Officer

Rune Skeie

44 2018 Chief Financial Officer

Anthony Brown

2018 Chief Scientific Officer

Alan Barge

59 2018 Interim Chief Medical Officer

Endre Kjaerland

Associate Director of IP and Contracts

Julia Schoelermann

Collaboration Manager

Victoria Wills

2016 Director of Clinical Operations

Steven Yule

Jon Eriksen

2012 Non-Executive Director

Sveinung Hole

2016 Non-Executive Director

Susan Foden

63 2016 Non-Executive Independent Director

Hilde Furberg

59 2017 Non-Executive Independent Director

Kari Gronas Dyvik

53 2016 Non-Executive Independent Director

Stener Kvinnsland

2015 Non-Executive Independent Director

Biographies

Name Description

Stein Annexstad

Mr. Stein Holst Annexstad has served as Independent Chairman of the Board at BERGENBIO ASA since January 16, 2017. He has been Non-Executive Director of the Company since February 1, 2016. Mr. Annexstad holds a BA in Commerce from the Norwegian School of Economics (1969). He has senior industry experience, both at executive and Board levels. He is former executive of Dyno Industrier AS (fine chemicals), and became the CEO of the pharmaceutical firm Nycomed AS (subsequently merged with Amersham Plc and thereafter merged with GE). He was head of AS Isco Group, an Executive Search and Corporate Advisory Group. Mr. Annexstad was in 1996 a co-founder of NorgesInvestor AS, an Oslo-based Private Equity firm, and was in 2008 the first Chairman of Investinor AS (the VC of the Norwegian State). At the same time he was Chairman of Algeta ASA, the pharmaceutical startup that successfully developed Xofigo (prostate cancer drug) and was acquired by Bayer Health Care in 2014. His other previous chairman positions comprise commercial banking, business school, public R&D and various industrial enterprises. He currently servesat VEAS-Vestfjorden Avlopsselskap (chairman), Asker Kommunale Pensjonskasse (board member) and Holstein AS (managing director and board member). Previously, he was employed at Algeta ASA (chairman), Investinor AS (chairman), Biomedisinsk Innovasjon AS (board member), Norsk Medisinsk Syklotronsenter AS (chairman), Agenda Kaupang AS (chairman) and Biotec Pharmacon ASA (chairman of the nominations committee).

Richard Godfrey

Mr. Richard S. Godfrey has served as Chief Executive Officer (CEO) of Bergenbio ASA since 2008. He has more than 28 years’ industry experience leading many international drug development and commercialization partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. He serves at Square One Holding AS (board member), Gnist Holding AS (managing director and chairman), Magnet Strategy and marketing Partners AS (board member), Biotec Pharmacon ASA (board member), Balter Medical AS (board member), Uni Targeting Research AS (chairman), Petosan AS (chairman) and Gnist Ltd (director). He was previously employed at Sarisa Venture management (board member and partner), Ayanda Group AS (board member) and Captech AS (board member).

Rune Skeie

Mr. Rune Skeie has been Chief Financial Officer at BERGENBIO ASA since March 5, 2018. He has over 20 years of financial management, corporate development, corporate governance and advisory experience with public and private companies across multiple industry sectors. The majority of his career was spent at EY (formerly Ernst & Young), where he held the role of Executive Director, before joining REMA Franchise Norge AS, the multinational supermarket business, as CFO. Mr. Skeie is a Registered Accountant and a State Authorized Public Accountant.

Anthony Brown

Dr. Anthony Brown Chief Scientific Officer of the company. He was Research Director at BERGENBIO ASA. He is founder and Director of Drug Discovery Limited and currently also Scientific Director at CellCentric. He has over 25 years of experience in the drug discovery of both small molecules and biological therapeutics. He has managed strategic alliances with Pharma and Biotech and lead several novel programs in Oncology, from early research through to clinical studies. Previously he has held Senior Management and Director level positions at British Biotech, OSI Pharmaceuticals, Piramed Pharma, Cancer Research Technology and more recently at CellCentric. He completed his doctorate from the University of Oxford in 1993 and MBA from Oxford Brookes University in 2008. He serves at Cerebellum Limited (director) and Drug Discovery Limited (director).Previously, he was employed at CellCentric Limited (scientific director).

Alan Barge

Dr. Alan Barge is Interim Chief Medical Officer of the company. Dr Barge is a board-certified oncologist and haematologist, with more than 25 years of experience in cancer drug development, spent primarily at AstraZeneca and Amgen. He spent over 12 years at AstraZeneca, where he was VP and Head Oncology and Infection, during which time he was responsible for the development of Iressa® (gefitinib) for non-small cell lung cancer (NSCLC) and the translational research that resulted in the successful personalised medicine strategy for AZ. Prior to AZ, Dr Barge was European and Global Medical Director at Amgen, at which he was responsible for European approval and label extensions for several of Amgen's cancer therapies. More recently, Dr Barge has been actively involved in the biotech sector in both CMO and non-executive positions, including CMO of Carrick Therapeutics (UK andIreland) and SVP Oncology at ASLAN Pharmaceuticals (Singapore).

Endre Kjaerland

Dr. Endre Kjaerland serves as Associate Director of IP and Contracts at BERGENBIO ASA. He joined BerGenBio AS in 2011 and is now head of intellectual property, quality systems and contracts. Prior to joining BerGenBio, he has gained more than 10 years of experience in academic science and supervision. He completed a Master of Science in molecular biology and Ph.D. in biochemistry from the University of Bergen.

Julia Schoelermann

Dr. Julia Schoelermann serves as Collaboration Manager at BERGENBIO ASA. She joined BerGenBio in 2015 in a business support role. She brings 10 years of hands-on laboratory and academic supervision experience from top European research institutions. Alongside she has worked several years as entrepreneurship community leader, advising IT and biotech startups as well as running own technology projects. She holds a Master of Science in biotechnology and biophysics from the University of Heidelberg as well as a Ph.D. in cell biology from the University of Bergen.

Victoria Wills

Ms. Victoria Elizabeth (Viki) Wills has been Director of Clinical Operations at BERGENBIO ASA since October 3, 2016. She brings over 30 years’ experience in the management of clinical programs from pharma, biotech and CRO companies across a number of therapeutic areas and phases, more recently focused on oncology. She qualified as a Pharmacist from Bath University and completed her post-graduate registration in Bristol, UK. She is Director of Mulberry Clinical Services Limited.

Steven Yule

Dr. Steven Murray Yule is no longer as Clinical Development Officer at BERGENBIO ASA, Effective from November 30, 2018. Dr. Murray Yule joined BerGenBio in 2011 as a consultant. He began his career in the pharmaceutical industry in 1998 after completing his medical training in oncology at Addenbrookes Hospital, Cambridge. Whilst working in the United Kingdom’s National Health Service, Murray supervised multiple early phase clinical studies of novel anticancer products and completed a PhD in experimental pharmacology. In the last ten years, whilst working in several top-ten pharmaceutical companies, he has planned and executed global development strategies for several anticancer drugs, which has led to licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia. Dr. Murray Yule also provides clinical development consulting to Incanthera Limited, Bicycle Therapeutics and the British Therapeutics Group. He serves at Pentlands Oncology Consulting Ltd (board member) and was previously employed at Pentlands Clinical Resourcing Limited (board member) and Astex Therapeutics Limited (medical director).

Jon Eriksen

Mr. Jon Oyvind Eriksen has served as Non-Executive Director at BERGENBIO ASA since January 30, 2012. He holds a Master of Science in biotechnology from the Norwegian University of Science and Technology (NTNU), and is a graduate degree in Russian and German from the University of Bergen who is currently employed as Investment Director at Investinor AS. He has been awarded an MBA with Distinction from London Business School, and he is also a CFA Charterholder. Mr. Eriksen is a serial entrepreneur with a proven track record of leading technology and media companies through start-up, growth, expansion and exits, mergers, acquisitions, corporate spin-offs and turnarounds. Mr. Eriksen has previously served as CEO of Kantega, Mogul Technology and Internet Aksess, and also held positions as chairman and member of the board of directors in several companies. He serves at Boostcom Group AS (board member), Novelda AS (board member), Signicat AS (board member), Sonstad AS (chairman), Unacast, Inc. (board member) and Swarm64 AS (board member). Previously, he worked for Numascale AS (deputy board member), Signicat AS (chairman) and Norwegian University of Science and Technology (NTNU) (board member and deputy board member).

Sveinung Hole

Mr. Sveinung Hole has served as Non-Executive Director of Bergenbio ASA since February 1, 2016. Sveinung Hole is the CEO of Bergen Research Foundation and the Kristian Gerhard Jebsen Foundation. Hole holds a number of Board positions amongst others at Sarsia Seed AS, Norwegian Venture Capital Association, Prophylix Pharma AS and VoluSense AS. Formerly, he was the CEO of the investment fund Sarsia Seed AS, Board Member of Bergen Hospital Trust (Helse Bergen) and Director of Anesthesia and Intensive Care at Haukeland University Hospital. Hole has also held various top management positions (Market, Strategy, Internet) at Telenor Corporation and been Regional Managing Director/Director of Global Strategies at the Berlitz Corporation. Hole holds a Master of International Management from BI Norwegian Business School. He serves at Pe Helse AS (chairman), Volusense AS (chairman), Nordic And Europe Health Invest AS (board member), Sarsia Seed AS (board member), Bergen Research Foundation (CEO), the Kristian Gerhard Jebsen Foundation (CEO) Prophylix Pharma AS (board member), Sarsia Seed Fond II AS (chairman) Tromso Forskningsstiftelse (board member). He previously was employed at Sarsia Seed Management (managing partner), Isentio AS (board member), Stiftelsesforvaltning AS (board member), Norwegian Venture Capital Association (board member), Bergen Hospital Trust (Helse Bergen) (board member), Nansen Neuroscience Network (board member) and BerGenBio AS (board member).

Susan Foden

Dr. Susan Elizabeth (Sue) Foden, Ph.D. has served as Non-Executive Independent Director of Bergenbio ASA since September 8, 2011. She was also Chairman of the Board of the Company until February 2016. She holds a number of Non-Executive Directorships with both public and private companies and public funding bodies in the biotech and healthcare field, including Vectura plc., Source Bioscience plc., Rainbow Seed Fund, Cascade Ltd and Oxford Ancestors Ltd. Previously, she held positions in venture capital and United Kingdom biotech companies. From 2000 to 2003, she was an Investor Director with the London-based VC firm Merlin Biosciences Limited, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology. She studied biochemistry at the University of Oxford from where she obtained a Master of Arts degree and Doctorate in Philosphy. She serves at British Technology Group Plc (board member), Vectura Group Plc (board member), Evgen Plc (board member), Oxford Ancestors Ltd (board member) Source Bioscience plc (board member), Rainbow Seed Fund (board member) and The Cell and Gene Therapy Catapult (board member). Previously, she was employed at Rainbow Seed Fund (board member), the Cascade Fund (board member), Cizzle Biotech Ltd (chairman), Rainbow Seed Fund Ltd and Source BioScience plc (board member).

Hilde Furberg

Ms. Hilde Furberg has served as Non-Executive Independent Director of BERGENBIO ASA since January 16, 2017. She was Chairman of the Board of the Company from February 2016 till January 16, 2017. Before that, she has been Non-Executive Director of the Company from June 22, 2015. Hilde Furberg has over 30 years of commercial experience in Pharma and Biotech, she is currently Senior Vice President Rare Diseases EMEA at Sanofi Genzyme. Previously her roles were Vice President and General Manager of Nordic Benelux and Nordic General Manager at Sanofi Genzyme. Prior to joining Genzyme, Ms. Furberg was Managing Director and part-owner of Pharmalink and held a number of roles at Baxter including Managing Director Sweden. She is currently Vice Chairman of the Board at Pharmalink AB and Board Member of J&J Future Invest AS, and has held board positions at Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA and Probi.

Kari Gronas Dyvik

Mrs. Kari Gronas Dyvik has served as Non-Executive Independent Director at BERGENBIO ASA since February 1, 2016. Kari Gronas (M. Sc. Pharm) has more than 25 years of experience in drug development and the commercialization of new products including securing regulatory approvals. She has significant management experience including leadership of cross functional and governance teams. She was SVP Operations at Algeta ASA, and has had leading positions in both Photocure ASA and Nycomed/Amersharm Health. She holds a non-executive directorship at Lytix Biopharma AS, is Chairman of the Board of the Norwegian Pharmaceutical Society, and is currently working as a consultant within biotech. She also serves at K og K AS (managing director) and The Federation of Norwegian Industry (member of board of representatives).

Stener Kvinnsland

Dr. Stener Kvinnsland has served as Non-Executive Independent Director at BERGENBIO ASA since September 1, 2015. Dr. Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr. Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan. He serves at Helse Stavanger Hf (chairman) and the Bergen Research Foundation (board member). Previously, he was employed at Oslo Universitetssykehus Hf (chairman) and Health Faculty at Tromso University (chairman).

Basic Compensation